(Q37981271)

26 August 2017

title

Treatment-emergent adverse events associated with atypical antipsychotics (English)

1 reference

26 August 2017

2

Roger S McIntyre

1 reference

26 August 2017

Danielle S Cha

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

5 February 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

11

1 reference

26 August 2017

page(s)

1587-1598

1 reference

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

A review of the safety and tolerability of aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Atypical antipsychotic tolerability and switching strategies in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Aripiprazole for the treatment of irritability associated with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Developmental origins of the metabolic syndrome: body clocks and stress responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Prevalence, detection, and management of the metabolic syndrome in patients with acute myocardial infarction: role of an obesity-centric definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Bipolar disorder and metabolic syndrome: an international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Waist circumference, visceral obesity, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Metabolic syndrome with the atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Side effects of atypical antipsychotics: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Effect of antipsychotic medications on glucose and lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

EEG abnormalities during treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Neurological complications of psychiatric drugs: clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Neuroleptic malignant syndrome secondary to quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

QT alterations in psychopharmacology: proven candidates and suspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Antipsychotic drug toxicology in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Fatal toxicity of drugs used in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Olanzapine-induced leucopenia and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Quetiapine-induced leucopenia and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Olanzapine-induced leukopenia with human leukocyte antigen profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Haematological toxicity of clozapine and some other drugs used in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Managing psychosis in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Use and safety of antipsychotic drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Clinical utilization of atypical antipsychotics in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Antipsychotic therapy during early and late pregnancy. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

Risperidone inhibits contractions induced by serotonin and histamine and reduces K+ currents in smooth muscle of human umbilical artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656590

10.1517/14656566.2012.656590

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference